PRESS RELEASE published on 07/03/2025 at 21:19, 9 months 28 days ago Inside Information / Operations of the issuer (acquisitions, sales...) GenSight Biologics closes EUR 3.9M private placement with issuance of ordinary shares, pre-funded warrants, investor warrants. Funds to repay convertible bonds. Maxim Group, LLC acted as placement agent Private Placement Ordinary Shares GenSight Biologics Maxim Group EUR 3.9M
BRIEF published on 07/01/2025 at 08:59, 9 months 30 days ago GenSight Biologics raises nearly €4 million in private placement Private Placement Investment GenSight Biologics Euronext Shares LUMEVOQ ®
PRESS RELEASE published on 07/01/2025 at 08:54, 9 months 30 days ago Inside Information / Operations of the issuer (acquisitions, sales...) GenSight Biologics successfully completes private placement of nearly EUR 4 million, attracting new international investors. Funds to advance gene therapies for retinal diseases and CNS disorders Private Placement GenSight Biologics Gene Therapies Retinal Diseases CNS Disorders
BRIEF published on 06/26/2025 at 07:35, 10 months 4 days ago GenSight Biologics: Advances in Manufacturing Partnership with Catalent Gene Therapy GenSight Biologics LUMEVOQ® NOHL Catalent
PRESS RELEASE published on 06/26/2025 at 07:30, 10 months 4 days ago Inside Information / Other news releases GenSight Biologics achieves significant milestone with new manufacturing partnership with Catalent, successfully transferring upstream phase of LUMEVOQ® manufacturing process Gene Therapy GenSight Biologics LUMEVOQ Catalent Manufacturing Partnership
BRIEF published on 05/13/2025 at 22:05, 11 months 18 days ago GenSight Biologics Shareholders Approve Majority of Board's Resolutions Shareholder Meeting Board Resolutions GenSight Biologics LUMEVOQ® Phase III RECOVER
PRESS RELEASE published on 05/13/2025 at 22:00, 11 months 18 days ago Inside Information / Other news releases GenSight Biologics announces approval of all resolutions at Combined General Meeting on May 13, 2025. Company highlights achievements of 2024 and strategic priorities for 2025 Strategic Priorities Approval Combined General Meeting GenSight Biologics Achievements
BRIEF published on 04/23/2025 at 20:35, 1 year ago GenSight Biologics Announces Annual General Meeting Details Annual General Meeting Shareholders Gene Therapy GenSight Biologics Retinal Diseases
PRESS RELEASE published on 04/23/2025 at 20:30, 1 year ago Inside Information / Other news releases GenSight Biologics to hold Annual General Meeting on May 13, 2025 at 2:00 pm CEST in Paris, France. Procedures for obtaining preparatory documents outlined Annual General Meeting Preparatory Documents GenSight Biologics Gene Therapies Retinal Diseases
BRIEF published on 04/08/2025 at 07:51, 1 year ago GenSight Biologics Files its 2024 Universal Registration Document AMF Gene Therapy Registration Document GenSight Biologics Retina
Published on 05/01/2026 at 00:45, 11 minutes ago Inventus Announces Closing of $2.5 Million Non-Brokered Flow-Through Financing
Published on 04/30/2026 at 23:55, 1 hour 1 minute ago Pinetree Capital Announces Unaudited Financial Results for the Period Ended March 31, 2026
Published on 04/30/2026 at 23:05, 1 hour 51 minutes ago AIP Realty Trust Announces Year End 2025 Results
Published on 04/30/2026 at 21:00, 3 hours 56 minutes ago Datavault AI Schedules Conference Call to Discuss First Quarter 2026 Financial Results on Friday, May 15, 2026
Published on 04/30/2026 at 23:39, 1 hour 17 minutes ago Anemoi International Ltd: Final Results For Year Ended 31 December 2025
Published on 04/30/2026 at 22:35, 2 hours 21 minutes ago Curaleaf Completes Buyout of Remaining Stake in Germany's Four 20 Pharma
Published on 04/30/2026 at 22:04, 2 hours 52 minutes ago Interim individual financial statements for the period ending on March 31, 2026 of Sirma Group Holding JSC
Published on 04/30/2026 at 19:00, 5 hours 55 minutes ago DOUGLAS Group grows sales in Q2 and updates full-year guidance on adjusted EBITDA
Published on 04/30/2026 at 19:00, 5 hours 56 minutes ago BioVersys announces approval of all Board Proposals at Annual General Meeting of Shareholders
Published on 04/30/2026 at 20:00, 4 hours 55 minutes ago AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 5 hours 40 minutes ago AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 5 hours 56 minutes ago Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 6 hours 46 minutes ago Minutes of the Combined General Meeting held on April 30, 2026
